Vimta Labs Limited
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries.
What Vimta files
- Others56
- Investor Meet46
- Board Meeting14
- PPTs10
- Updates9
- Dividend/Bonus8
Vimta Labs' Q1 FY27 total income rose 13.7% YoY to ₹112.9 Cr, with PAT at ₹21.0 Cr (+11.4% YoY). Pharma services saw healthy growth. New Biologics CRADS operations commenced. Food testing is adapting to headwinds via domestic market penetration.
Vimta Labs posted FY26 revenue of Rs. 416.3 Cr, up 19.5% YoY, and PAT of Rs. 77.5 Cr, up 16.1%. Q4 revenue reached Rs. 112 Cr. Strong growth was driven by Pharma and Food divisions, following the divestment of its Diagnostics business in FY25.
Vimta Labs reports Q3 FY26 results. Total Income rose 10.2% YoY to Rs. 100.5 Cr. EBITDA at Rs. 34.4 Cr (34.3% margin) and PAT at Rs. 17.6 Cr (17.5% margin), reflecting strong demand and efficiency.
Vimta Labs posted record Q2 revenue of 104.5 Cr, up 22.3% YoY. EBITDA margin was 35.3%, PAT margin 19.1%. H1 revenue reached 203.8 Cr, up 26.6%. Growth driven by Pharma and Food testing services. The company also achieved a successful WHO audit for Clinical Research.
Vimta Labs received stock exchange approval to list 1,181,494 ESOP shares, including 518,260 post-bonus issue. This moves the employee stock option plan forward, potentially increasing outstanding shares.